UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Clinical trials for UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy combo aims to extend life in stage 3 lung cancer
Disease control OngoingThis phase III trial studies whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with stage 3 non-small cell lung cancer that cannot be surgically removed. About 660 participants will receive either chemoradiation plus durvaluma…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 06:00 UTC
-
New combo aims to control lung cancer when immunotherapy fails
Disease control OngoingThis phase 2 study tests a new drug (pevonedistat) combined with two standard chemotherapies (carboplatin and paclitaxel) in 27 adults with advanced non-small cell lung cancer that has not responded to immunotherapy. The goal is to see if this combination can shrink or control th…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Nanoparticles could supercharge radiation against returning lung tumors
Disease control OngoingThis early-phase trial tests whether adding NBTXR3 nanoparticles to radiation therapy can safely treat inoperable non-small cell lung cancer that has come back after prior radiation. The nanoparticles are designed to concentrate radiation energy inside tumor cells, potentially ki…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo therapy targets tough lung cancer in early trial
Disease control OngoingThis early-phase study tests the safety and best dose of a new drug, minnelide, when given with the standard drug osimertinib for people with advanced EGFR-mutated non-small cell lung cancer. The trial enrolls about 8 adults whose cancer has spread or cannot be removed by surgery…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo aims to fight lung cancer without chemo
Disease control OngoingThis early-phase trial tests whether combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy is safe and effective for patients with stage II or III non-small cell lung cancer that cannot be surgically removed. The study enrolls 21 participants who hav…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo aims to control advanced lung cancer
Disease control OngoingThis study tests a combination of two drugs—pembrolizumab (an immunotherapy) and trametinib (a targeted therapy)—in people with advanced non-small cell lung cancer that has come back or spread. The goal is to see if the combination is safe and can shrink or control tumors. Partic…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Cancer vaccine plus immunotherapy shows promise in Hard-to-Treat cancers
Disease control OngoingThis study combines the CIMAvax EGF vaccine with immunotherapy drugs (nivolumab or pembrolizumab) to treat advanced non-small cell lung cancer and squamous head and neck cancer. The vaccine aims to slow tumor growth, while the immunotherapy helps the immune system attack cancer c…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Smart radiation planning may ease lung cancer treatment side effects
Symptom relief OngoingThis study looks at whether updating radiation treatment plans at set times (adaptive planning) can lower side effects like lung inflammation in people with stage II-IV non-small cell lung cancer. About 34 participants will receive standard radiation and immunotherapy, but their …
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC